%0 Journal Article %A Zixin Hu %A Qiyang Ge %A Li Luo %A Tao Xu %A Kai Zhang %A Henry H Lu %A Wei Li %A Eric Boerwinkle %A Li Jin %A Momiao Xiong %T Population Vaccine Effectiveness and its Implication for Control of the Spread of COVID-19 in the US %D 2021 %R 10.1101/2021.04.30.21256228 %J medRxiv %P 2021.04.30.21256228 %X Realized vaccine efficacy in population is highly different from the individual vaccine efficacy measured in clinical trial. The realized vaccine efficacy in population is substantially affected by the vaccine age-stratified prioritization strategy, population age-structure, non-pharmaceutical intervention (NPI). We proposed a population vaccine efficacy which integrated individual vaccine efficacy, vaccine prioritization strategy and NPI to measure and monitor the control of the spread of COVID-19. We found that 11 states in the US had low population vaccine efficacy and 20 states had high population efficacy. We demonstrated that although the proportion of the population who received at least one dose of COVID-19 vaccine across 11 low population vaccine efficacy states, in general, was greater than that in 20 high population vaccine efficacy states, the 11 low population vaccine efficacy states experienced the recent COVID-19 surge, while the number of new cases in the 20 high population vaccine efficacy states exponentially decreased. We demonstrated that the proportions of adults in the population across 50 states were significantly associated with the forecasted ending date of the COVID-19. We show that it was recent low proportion of adults vaccinated in Michigan that caused its COVID-19 surge. Using population vaccination efficacy, we forecasted that the earliest COVID-19 ending states were Hawaii, Arizona, Arkansas, and California (in the end of June, 2021) and the last COVID-19 ending states were Colorado, New York and Michigan (in the Spring, 2022).Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr. Li Jin was partially supported by National Natural Science Foundation of China (91846302). Dr. Wei Lin is supported by the National Key R&D Program of China (Grant no. 2018YFC0116600), by the National Natural Science Foundation of China (Grant nos. 11925103 & 61773125), and by the STCSM (Grant no. 18DZ1201000). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We used public data. Exemption for IRB.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be freely downloaded. https://ourworldindata.org/covid-vaccinations https://coronavirus.jhu.edu/MAP.HTML %U https://www.medrxiv.org/content/medrxiv/early/2021/05/05/2021.04.30.21256228.full.pdf